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1. Introduction
1.1 The National Service Framework for Children, Young People and Maternity
Services establishes clear standards for promoting the health and well-being
of children and young people and for providing high quality services which
meet their needs.
1.2 There are eleven standards, of which this is the tenth. They cover the
following areas:
Standard 1 Promoting Health and Well-being, Identifying Needs and Intervening Early
Standard 2 Supporting Parenting
Standard 3 Child, Young Person and Family-centred Services
Standard 4 Growing Up into Adulthood
Standard 5 Safeguarding and Promoting the Welfare of Children and Young People
Standard 6 Children and Young People who are Ill
Standard 7 Children and Young People in Hospital
Standard 8 Disabled Children Young People and those with Complex Health Needs
Standard 9 The Mental Health and Psychological Well-being of Children and Young People
Standard 10 Medicines for Children and Young People
Standard 11 Maternity Services
1.3 This chapter addresses the use of medicines for children and young people
and should be read in conjunction with all the other Standards. The use of
medicines in pregnancy is addressed in Standard 11.
1.4 Use of medicines is a integral component of each of the National Service
Framework standards. There are medicines elements which apply to every
standard, for example, ensuring children and young people in all settings
have access to safe and clinically effective medicines in appropriate
formulations; that staff are able to advise parents or carers and children and
young people about their medicines, and that children, young people and
their parents or carers have ready access to up-to-date information which is
consistent and based on the best available evidence.
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Standard 10: Medicines for
Children and Young People
Vision
We want to see:
> All children and young people receiving medicines that are safe and effective, in
formulations that can easily be administered and are appropriate to their age,
having minimum impact on their education and lifestyle.
> Medicines being prescribed, dispensed and administered by professionals who
are well-trained, informed and competent to work with children to improve
health outcomes and minimise harm and any side effects of medicines. 
> Children and young people and their parents or carers who are well-informed
and supported to make choices about their medicines and are competent in the
administration of medicines. 
Standard: 
Children, young people, their parents or carers, and health care professionals in
all settings make decisions about medicines based on sound information about
risk and benefit. They have access to safe and effective medicines that are
prescribed on the basis of the best available evidence. 
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Markers of Good Practice
1. The use of medicines in children is based on the best available evidence of
clinical and cost-effectiveness and safety, ideally derived from clinical trials,
but also including, where appropriate, medicines that are not licensed for
their age group or for their particular health problem (‘off-label’), or those
that do not have a licence at all (‘unlicensed’) in order to achieve the best
possible health outcomes and minimise harm and side effects.
2. In all settings and whatever the circumstances, children and young people
have equitable access to safe, clinically and cost-effective medicines in age-
appropriate formulations.
3. Appropriate information and decision support is available for professionals who
prescribe, dispense and administer medicines for children and young people.
4. Children, young people and their parents/carers receive consistent, up-to-date,
comprehensive, timely information on the safe and effective use of medicines.
5. In all settings, professionals enable parents, young people and, where
appropriate, children to be active partners in the decisions about the
medicines prescribed for them.
6. Primary Care Trusts, NHS Trusts and other organisations ensure that the 
use of medicines in children is incorporated in their clinical governance and
audit arrangements.
7. The contribution of pharmacists in the effective and safe use of medicines in
children is maximised.
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2. Rationale 
2.1 Children are different from adults, their bodies respond to medicines differently
from those of adults, and young children differently to older children. Thus
detailed care and attention needs to be paid when making prescribing decisions
for children and young people, taking into account their age, weight and
developmental stage. Lack of evidence on the use of medicines in children and
young people leads to uncertainty in dosing and, even at the most appropriate
dose, may lead to differences in effectiveness and adverse effects to those
seen in adults.
2.2 The evidence suggests that medication safety needs to be improved,
particularly in babies and young children. In a hospital setting, medication
errors in children occur at similar rates to adults but have three times the
potential to cause harm. 
2.3 When most new medicines are licensed or receive their Marketing
Authorisation, they are only licensed for use in adults. This is because, on the
whole, the manufacturer only investigates their safety and efficacy in the
adult population. This may be either because there may be little commercial
incentive to carry out studies in children, or because of an inability to recruit
enough children into clinical trials. In 2004, the Government recognised the
need for high quality research in children and young people and resolved to
establish a national research network to study medicines for children. 
2.4 Medicines prescribed for a child that are not licensed for that age group or for
their health problem are referred to as ‘off-label’ and medicines that do not have
a licence at all as ‘unlicensed’. The informed use of unlicensed medicines or of
medicines for unlicensed applications (‘off label’ use) is thus often unavoidable
for children if they are to have access to the most effective medicines. 
2.5 Misunderstanding the role of medicines in controlling long-term conditions
leads to reduced compliance. It follows that better information, education
and the involvement of parents and children in the decisions about their
medicines should improve compliance, reduce the wastage of medicines and
hence of NHS resources, improve quality of life and health outcomes. 
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Rates of compliance in children have been reported to range from 25-82%.
There is evidence of adverse consequences because of low compliance in
prophylactic antibiotic treatment, asthma, epilepsy and lymphoblastic leukaemia.
Adolescence poses a special challenge when it comes to compliance with
treatment; evidence shows low rates of compliance in, for example, cystic
fibrosis, epilepsy, diabetes and asthma. 
2.6 The age at which children are ready to take care of, and be responsible for,
their own medicines, varies. Health professionals need to assess, with parents
and children, the appropriate time to make this transition. 
2.7 Some children and young people, particularly those who are disabled or have long
term conditions, have to take medicines during the school day, and with some
assistance from health, early years or school staff they are able to take part in most
activities. There is, however, anecdotal evidence that the storage of medicines and
access to medicines in these settings can vary. It is therefore important that local
health and education services work together to ensure that children and young
people are able to receive their medicines during the school day. 
2.8 The use of medicines is the most common therapeutic intervention carried
out in the NHS. This standard addresses the need to ensure the child or
young person’s safety, through the appropriate prescribing and delivery of
both licensed and unlicensed medicines. It highlights the need to ensure
equal access to medicines for all children and young people who require
them through improved planning and collaborative arrangements.
Partnership between professionals and parents or carers and their children
and the provision of high quality information is crucial to ensure concordance
and improve outcomes for children and young people.
2.9 Management of Medicines: A resource to support implemetation of the
wider aspects of medicines management for the national service frameworks
for diabetes, renal services and long-term conditions1 will also be useful.
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Interventions
3. Safe Medication Practice 
3.1 Errors in prescribing and administration of medicines to children are at least
as common as in adults. However, the consequences of these errors can be
more serious. A study of admissions to neonatal and paediatric intensive care
units found an error rate of 1 every 6.8 admissions (14.7%). The risk of error
in children is often compounded by the need for additional calculations to
determine the dose.
3.2 Lack of formulations of licensed medicines for children frequently necessitates
the use of products made for adults and hence the need for the calculation of
doses and accurate measurement of small liquid dose volumes. A common
source of error is misplacement of decimal points in dose calculations.
Sometimes complex manipulations are necessary to prepare doses for very
small babies.
3.3 Access to appropriate formulations of medicines that can be easily
administered and are palatable is another important consideration. Some
children may be able to and may prefer to take solid dosage forms. 
3.4 A large number of medicines that are prescribed or dispensed to children
contain suger and are a potential cause of tooth decay. These medicines are
often taken on a regular basis and are given last thing at night when there is
less saliva to protect teeth from the impact of acid produced by the sugar in the
medicine. Avoidance of sugared medicines is especially important in preventing
tooth decay in chronically sick children needing medication on a regular basis.
3.5 Children may be more susceptible than adults to the toxic effects of some
medicines, for example, propofol and sodium valproate. The converse is true
for some other medicines, where children require higher doses than adults on
a weight for weight basis because of increased rates of metabolism (for
example, theophylline). 
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3.6 The Chief Pharmaceutical Officer’s Report, Building a Safer NHS for Patients –
Improving Medication Safety2 explores the causes and frequency of medication
errors, highlights medicines and clinical settings that carry particular risks, and
identifies models of good practice to reduce risks. The report should be used
to inform practice for the use of medicines for children and young people. 
Primary Care Trusts and NHS Trusts ensure that:
> Individuals who prescribe, dispense or administer medicines to children are able to
demonstrate competence in the use of medicines in children, including dose and
infusion calculations; this is achieved through continuing professional development; 
> Standardised charts or aide-memoirs or, preferably, validated computer software
for calculating doses and infusion rates are available for potent medicines such as
digoxin and opiates;
> Drugs with high risk potential in paediatric practice are identified and the National
Patient Safety Agency works with paediatric practitioners to analyse errors and
improve ways of managing medicines, in order to reduce medication errors;
> Dose, volume and rate calculations are carefully checked and documented prior
to the administration of medicines;
> The child’s age, weight and intended dose in mg/kg is included on all
prescriptions for medicines of high risk, where available;
> There is prominent documentation of the allergy status in patient records which
is available when prescribing medicines;
> Oral syringes of appropriate size are used to administer all liquid medicines when
the volume required does not correspond to a 5ml spoonful. For babies and
younger children, it may be appropriate to use oral syringes rather than spoons
to facilitate administration of all liquid medicines;
> Injection syringes are not normally used to administer oral medicines or feeds;
> If crushing tablets or opening capsules is unavoidable (for example, for
administration through feeding tubes), the advice of a pharmacist is sought;
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> Professionals are aware that excipients in medicines also have the potential to
cause adverse effects in children. Examples include aspartame in children with
phenylketonuria, lactose in individuals with lactose intolerance, and colourings
and preservatives in those with intolerance to these ingredients;
> Medication errors are reported through local systems as well as national
reporting and learning systems, and
> Individuals who prescribe, dispense or administer medicines to children should be
aware of the availability of sugar-free alternatives and ensure that where possible
these are prescribed or dispensed in preference.
4. Unlicensed and Off-label Medicines
4.1 Almost three quarters of medicines prescribed in neonatal intensive care units
are prescribed outside of licensed indications. On children’s wards, around one
quarter of medicines are prescribed outside licensed indications (“off-label”)
in the UK and over one third of children received at least one such medicine.
In paediatric pain management, 33% of medicines are prescribed off-label
and in paediatric gastroenterology, the figure is 49%. In general practice, at
least one in ten medicines prescribed for children are off-label or unlicensed.
4.2 In ideal circumstances, children and young people should have access to
licensed formulations which are appropriately evaluated for use in children.
However, due to a lack of licensed formulations for children, in many
circumstances, the only alternative to use of licensed adult formulations is
customised preparation of suitable formulations in the pharmacy. A range of
guidance is available to inform practice in the use of unlicensed and off-label
medicines as listed in Box 1.
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Box 1: Guidance for the Use of Unlicensed and Off-label Medicines
The Hospital Medicines Management (MM) Framework3
(www.dh.gov.uk/assetRoot/04/06/82/07/04068207.pdf) includes standards for
the use of unlicensed medicines. Standard 33 and 34 make it clear that unlicensed
medicines should be subject to the same clinical governance procedures as 
licensed medicines.
A Guide to Preparation of Non-Sterile Extemporaneous Products in NHS Hospitals 4
has recently been published by the NHS Pharmaceutical Quality Assurance
Committee. (Available from vfm@stmarys.demon.co.uk).
4.3 European legislation is in progress to provide obligations and incentives to
develop medicines for use in children where there is a therapeutic need. This
should result both in more medicines being licensed for use in children and in
new information for prescribers regarding contraindications, special precautions
for use and monitoring, as well as providing more information for children,
young people and their parents or carers. The legislation to enable more
products to be available for children should be in place by 2006. In the
meantime, work is progressing to encourage the pharmaceutical industry to
make more formulations available for children. 
4.4 A programme for the modernisation of NHS medicines manufacturing
services is underway to ensure that NHS pharmacy services have the capacity
to provide the medicines patients need, where appropriate licensed products
are not available from the pharmaceutical industry.
11
Primary Care Trusts and NHS Trusts ensure that:
> Customised formulations for individual children are only used when the patient
has a clinical need that cannot be adequately met by a licensed medicine;
> Prescribers, dispensers and those administering medicines are able to show that
they adhere to the Hospital Medicines Management (MM) Framework standards
for the use of unlicensed medicines and that this is overseen by the Drugs and
Therapeutics Committee;
> In primary care, the use of unlicensed medicines is overseen by the Area
Prescribing Committee (or equivalent);
> Facilities and equipment used for extemporaneous dispensing are appropriate
and this work is carried out by trained staff under the supervision of a
pharmacist and following national guidelines, and
> Community and hospital pharmacies that do not have a manufacturing licence
(where products are prepared in accordance with a prescription under the
exemptions conferred on pharmacies under Section 10 of the Medicines Act),
follow national guidance (Guide to the Preparation of Non Sterile
Extemporaneous Products in NHS Hospitals4).
5. Enhanced Decision Support for Prescribers
5.1 The evidence base for the use of medicines in children is weak in comparison
to that for adults. Many medicines used in children do not have a Marketing
Authorisation or licence relating to use in children and it is accepted that
good practice includes using medicines for which there is a ‘sound theoretical
basis’, supported by information and/or experience, for believing that they
are effective in children. 
5.2 Prescribing medicines for children can be challenging, especially for those
professionals who do not routinely work within children’s services. The doses
of medicines prescribed need to take account of the age and weight of the
child, their developmental stage and co-morbidities. 
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5.3 The British National Formulary for Children will provide authoritative and up-
to-date advice on the use of medicines in children. It will be produced by an
expert Formulary Committee, will take account of recent NICE and CSM
guidance, will be revised annually, and will be distributed to doctors and
pharmacists. Its format will resemble the adult BNF, and an electronic 
version is also planned.
5.4 The evidence base on safety and efficacy of complementary therapies is
sparse and data are still emerging on possible risks, for example, interactions
between herbal and conventional medicines and toxicity from herbal
medicines. Parents, young people and health professionals need better
information on the safety and efficacy of complementary therapies. 
See section 9.6
5.5 More information is needed for those prescribing medicines for children
receiving palliative care and there is a lack of research data to support
prescribing of many medicines for palliative care. Cancer Networks are
developing palliative care formularies for children.
5.6 Effective communication is required between hospital consultants and
general practitioners. Children and young people and their parents or carers
sometimes experience difficulty in accessing medicines in the community
following discharge from hospital resulting in confusion and anxiety for
parents, carers and young people. EL (91) 1275 provides guidance on
responsibility for prescribing between hospitals and general practitioners,
and focuses on the concept of shared care. It emphasises the need for good
communication between prescribers in secondary and primary care.
Information exchange can also be facilitated by the use of Personal Child
Health Records and/or compatible, electronic information systems. 
See Standard 3
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Primary Care Trusts and NHS Trusts ensure that:
> Health professionals who prescribe, dispense and administer medicines for
children are able to access support and information from paediatric specialists
who have the knowledge and expertise in the handling of medicines by children.
In NHS Trusts, this can be achieved through the Medicines Information Network;
> To reduce avoidable problems when a child is transferring between secondary
and primary care, clear and prompt written communication takes place between
hospital specialists, general practitioners and, where appropriate, the community
pharmacist, about the medicines and doses they have prescribed for a child, and
> Personal Child Health Records are used as well as NHS-based records when medicines
are unusual, or when the dose is changed frequently. Hospital pharmacists
communicate directly with colleagues in other hospitals and in the community
when a child or young person is transferred or discharged, when medicines are
unusual, require special preparation or consideration, or are difficult to obtain.
6. Improving Access to Medicines
6.1 Access to safe and effective medicines for children and young people needs
to be enhanced. Some medicines that are used in children may be unfamiliar
to doctors and pharmacists who do not work regularly with children. Some
may be difficult to obtain in the community. Access to medicines which are
obtainable only from hospital pharmacies can cause inconvenience, distress
and frustration for children, young people, parents or carers.
6.2 Over the next few years, prescribing responsibilities will be extended to
health professionals other than doctors. Currently, there are extended
formulary nurse prescribers and supplementary prescribing pharmacists and
nurses helping to improve access to medicines and choice for patients. It is
proposed that the formulary for extended formulary nurse prescribers will be
expanded over time. Supplementary prescribing will enable pharmacists and
nurses to prescribe medicines outside licensed indications provided these are
included within individualised clinical management plans. These new
prescribers should be supported and used where it is appropriate and safe to
do so. Work has also commenced to enable allied health professionals to
become supplementary prescribers.
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6.3 Appropriate use of Patient Group Directions, independent and supplementary
prescribing and review of traditional medicines supply systems can help to
improve access by ensuring that prescribing, administration and supply of
medicines are convenient and suit the needs of young people and their
parents or carers. It also improves choice for patients in accessing medicines
and utilises professional skills better.
6.4 ‘One stop’ dispensing to speed up discharge, re-use of patients’ own
medicines and patient/parent self-administration of medicines has now been
implemented, where appropriate, in the majority of hospitals. Best practice in
these areas should be further spread. The forthcoming Hospital Medicines
Management Collaborative will help to address this.
6.5 Access to Controlled Drugs for use in palliative care in the home can cause
problems over transportation, disposal and documentation. Guidance from
the National Prescribing Centre, A guide to good practice in the management
of controlled drugs in primary care (England)6 (www.npc.co.uk) will help to
address some of these issues.
6.6 Enhanced availability of medicines, including those for palliative care and
associated out-of-hours advice, is needed. An out-of-hours medicines supply
guide will be published during 2004 which will include a formulary for use
out-of-hours7.
6.7 Compliance aids may assist some children and their families in managing their
medicines. Before children are given compliance aids, an assessment should
be undertaken to ascertain if they are appropriate. 
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Primary Care Trusts and NHS Trusts work collaboratively to ensure that there is
equitable access to clinically and cost-effective treatments in all settings. 
Primary Care Trusts and NHS Trusts review their policies and practices to ensure
that non-medical prescribing and the use of Patient Group Directions are used
where clinically appropriate and safe for patients, to enhance access and meet 
the needs of children and their families. 
When children or young people with long term conditions or their parents or
carers are competent in managing their medicines, they are allowed to do so
during hospital stays. Care given in hospital is, as far as possible, similar to that
given at home. 
Primary Care Trusts and NHS Trusts ensure that NICE appraisals and guidelines are
available and incorporated into local practice. 
Pharmacists provide compliance aids where appropriate and agreed locally, carry
out regular medication reviews for those children and young people on complex
long-term treatments, and advise on appropriate formulations of prescribed
medicines and on the treatment of minor ailments.
7. Information for Children and Young People and their Parents or Carers
See Standards 2 and 3
7.1 Clear, understandable and up-to-date information is required, in a variety of
media, formats and languages including an honest assessment of the risks
and benefits of medicines, side effects and long-term effects. Improved
availability of information can contribute to concordance.
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7.2 Young people and their parents or carers do not always have access to
information about “off-label” use of medicines. The standard manufacturers’
Patient Information Leaflet (PIL) only provides information for licensed
indications and if medicines are not licensed for use in children, will state that
it should not be used for children. This can be a source of confusion and
potential concern for children and their families. PILs produced by manufacturers
of medicines may not always be easily understood by children (and some
adults) and usually they are not available in foreign languages. Consideration
needs to be given to make available information when unlicensed medicines
and off-label medicines are dispensed so that parents, children and young
people can be supported in the use of these medicines.
7.3 A study of the readability of 10 manufacturers’ Patient Information Leaflets
for commonly-used medicines for children showed that nine could not be
read at a reading age of 13 (9% of adults read at that level). The needs of
patients whose first language is not English need to be better met. Use of the
websites www.mypil.com and www.harpweb.org.uk could help to meet the
needs of these people.
7.4 Provision of general information of the reasons why some medicines for
children and young people are unlicensed or used outside the terms of their
licence can supplement information provided by doctors and pharmacists. Two
Patient Information Leaflets (one for parents/carers and one for older children)
have been produced by the Joint Standing Medicines Committee of the Royal
College of Paediatrics and Child Health and the Neonatal and Paediatric
Pharmacists’ Group and are available on their website –
www.rcpch.ac.uk/publications/formulary_medicines.html. 
7.5 Pharmacists and other staff can support parents or carers and children and
young people in providing information about medicines and promoting the
use of information resources such aswww.nhs.direct.uk, www.dipex.org, 
and www.teenagehealthfreak.org. Medicine-specific information is being
developed for all medicines used within paediatrics, focusing on the needs 
of children, young people, parents and carers.
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Primary Care Trusts and NHS Trusts ensure that:
> Tailored information is provided to young people and their carers, where
available, for off-label or unlicensed medicines, to explain the use of the
medicine for their particular condition;
> Labels in larger type and Braille are, where possible, provided for parents and
children and young people who are visually impaired;
> Innovative ways to get messages across to parents or carers and children and young
people are considered (for example, using computer games or text messaging), and
> Young people and parents or carers receive copies of relevant letters about their
health. Health professionals may need to develop appropriate writing styles for this.
8. Concordance and Partnership in Taking Medicines 
8.1 The concept of compliance (the extent to which the prescriber’s instructions
are followed) is now widely regarded as outdated. Instead the aim is to
achieve concordance, where there is shared decision-making between parents
or carers, children and young people, and professionals. Time and effort
invested in a concordant discussion between the health care professional and
the child or young person and their family in their treatment should result in
more effective use of medicines. Children and young people and parents or
carers need to be helped to be active partners in discussions about their
medicines, in which the risks and benefits of treatment are discussed, taking
into account their values and beliefs, as well as the effects of the proposed
treatment on daily living.
8.2 Moving from the traditional model of compliance towards concordance will
involve learning and a culture change for health professionals, children and
parents. The Medicines Partnership Taskforce is developing training for
clinicians on concordant medication reviews in epilepsy for doctors, nurses
and pharmacists. Learning from this initiative could be used to spread good
practice for other medical conditions. (See www.medicines-partnership.org).
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8.3 As children grow and develop, they should be encouraged to participate in
decisions about their medicines and to take responsibility for taking their
medicines. Older children with a long-term illness should, where possible,
assume complete responsibility under the supervision of their parent/carer.
Children develop at different rates and hence their ability to take
responsibility for their own medicines varies. This should be borne in mind
when making a decision about transferring responsibility to the child or
young person for their own medicines. There is no set age when this
transition should be made. Health professionals should assess, with each
individual child, parents and/or carers when they can and want to be
responsible for their own medicines. See Standards 3 and 4
Clinicians are able to demonstrate that they have sought and acted on patients’
and their parents or carers views and that patients’ agreement was sought for the
medicine regime they have jointly agreed, especially for children or young people
with long term or complex medication needs.
Young people, children and their parents or carers are involved in the design and
delivery of professional development programmes on concordance.
Primary Care Trusts and NHS Trusts ensure that appropriate guidance is followed
for consent and the use of medicines in children and young people. 
See Standards 3 and 7
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9. Medication Review
9.1 Medication review has been defined as: “A structured, critical examination of
a patient's medicines with the objective of reaching an agreement with the
patient about treatment, optimising the impact of medicines, minimising the
number of medication-related problems and reducing waste”8. 
9.2 The report of the national clinical audit of Sudden Unexpected Death in
Epilepsy (SuDEp) found inadequate medicines management in 47% of deaths
in children9. Aspects identified include prescribing of inappropriate drugs and
doses, and lack of regular medication reviews. The audit also found that
children and parents received insufficient information, especially about the
side effects of medicines and the possibility of sudden death from epilepsy. 
9.3 There is good evidence to show that medication reviews can improve safety,
enhance appropriateness of prescribing and reduce unnecessary use of
medicines resulting in improved health outcomes. Medication reviews can
identify inappropriate doses being prescribed (too high or too low), side
effects that a patient may be experiencing, the information needs of patients,
and when to change or stop treatment. 
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9.4 A concordant discussion during a medication review can provide an opportunity
to discuss reasons for non-compliance with prescribed medicines. Medication
reviews also provide an opportunity to carry out a wider review of the patient’s
clinical condition, which may involve different health professionals. The Medicines
Partnership has developed a medication review guide for both professionals
Room for Review 8 and patients/parents Focus on your Medicines - a patient
guide to medication review10. See www.medicine-partnership.org/welcome
9.5 Reviewing and improving repeat prescribing systems, which identify when a
medication review needs to be carried out, can be beneficial for patients. The
National Prescribing Centre published Saving time, helping patients: A good
practice guide to quality repeat prescribing11 in January 2004, a resource to
help general practices to review their repeat prescribing processes and to
develop services that are efficient, effective, safe and convenient for patients,
carers, and healthcare staff. This guide has been commended by the Royal
College of General Practitioners and the General Practice Committee
Prescribing sub-committee of the British Medical Association.
9.6 It is important that medication histories take account of the use of complementary
therapies. Parents may feel discouraged from discussing complementary
therapies in consultations with health professionals, resulting in incomplete
medication histories.
Primary Care Trusts and NHS Trusts ensure that:
> All children with epilepsy have regular medication reviews (in line with the
SuDEp recommendation);
> Mechanisms are in place for regular review of medicines used to treat children
and young people with complex, long term conditions;
> There is equitable access to medication reviews, where appropriate, for children
in all settings including children’s homes and young offenders institutions, and
> Professionals taking medication histories ensure that the use of complementary
therapies is taken into account.
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10. Medication at Home, in Care and Education Settings
Home and Care Settings
10.1 Homecare and outreach services are increasingly being used, through the
development of Children’s Community Teams (see Standard 6), with the aim
of managing patients in or as close to their own homes as possible. Some
medicines prescribed for children in these settings require complex administration
arrangements. This creates a requirement for greater support for parents or
carers who administer increasingly complex medicines in the home. The use
of insulin pumps at home, for example, is increasing.
10.2 The incidence of accidental poisoning is unequal across socio-economic groups,
and is most common among children from the most disadvantaged families.
Child resistant containers have reduced deaths in children through accidental
ingestion but there remains a need for vigilance by parents or carers. 
NHS Trusts ensure that parents or carers of children (and, where appropriate,
children and young people themselves) on complex medical regimes are supported
and trained in the use of these medicines prior to discharge from hospital.
Further support is given by healthcare professionals to help children, young people
and their parents or carers when changes to complex treatment are made.
When prescribing, dispensing and administering medicines for either adults or
children or young people who are at home, healthcare professionals alert parents
or carers to the potential dangers of the medicines and advise them on appropriate
storage.
Early Years and Childcare Settings 
10.3 Day care providers are required under the Children Act 198912 to adhere to
the national standards for day care and childminding13 of children under eight
years of age. The Administration and Control of Medicines in Care Homes and
Children’s Services14, published by the Royal Pharmaceutical Society of Great
Britain provides advice on the provision, supply and storage of medicines to
22
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enable services to meet national standards for handling medicines safely.
These standards set out the requirements for child care in early years settings
in the private, voluntary and maintained sectors. Providers must have a
clearly understood policy on the administration of medicines. This includes
storage, record-keeping, written parental consent and a training requirement
if the administration of prescription medicines requires technical or medical
knowledge. Medicines must be stored safely and be inaccessible to children.
The national standards also include a first aid training requirement. 
Primary Care Trusts and Local Authorities ensure that staff working in early years
and childcare settings have access to appropriate advice, training and support from
local health agencies to help them fulfill their requirements on the management of
prescribed medicines.
Policies are in place for the safe storage, supply and administration of medicines.
Schools 
10.4 Government guidance for schools Supporting pupils with medical needs: a
good practice guide15, has been written to help schools draw up policies on
managing medicines in schools, and to put in place effective management
systems to support individual pupils with medical needs. The accompanying
Circular 14/96 Supporting pupils with medical needs in school16, 1996 sets
out the legal framework for mainstream schools and local education
authorities in supporting pupils with medical needs. 
10.5 Most children who need their medicines during the school day can attend
school regularly and, with some support from their school, can take part in
most normal school activities. Appropriate training and support from
healthcare professionals can enable schools to support pupils with their
medicines. For teachers, and most school support staff, managing a pupil’s
medicine is a voluntary role additional to their other duties. 
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10.6 Local healthcare professionals (such as school nurses), play a vital role in
helping ensure pupils receive their medicine during the school day, by
providing training and support to schools. All schools - including mainstream,
special and residential – need the dedicated support of local health professionals
if pupils are to have access to their medicines and to ensure that all medicines
are managed safely by schools.
10.7 The use of Controlled Drugs in schools is sometimes essential, e.g. for
children and young people who require methylphenidate for Attention Deficit
Hyperactivity Disorder. The safe storage and use of these drugs can present
problems for the school. There are plans for formalising through legislation,
the management of Controlled Drugs in institutions including schools.
10.8 Schools need to consider carefully their arrangements for managing an
individual pupil’s medicine. Ultimately, the employer of school staff at a
maintained school (either the Local Authority or the school’s governing
body), has responsibility for the health and safety of staff, pupils and visitors
and must be satisfied that the arrangements for managing medicines safely in
school protect - as far as is reasonably possible - the health and safety of
staff, pupils and visitors. 
10.9 Some medical conditions may be classed as a disability. Part 4 of the Disability
Discrimination Act (DDA) places duties on the responsible body of a school and
it will need to consider what arrangements can reasonably be made to help
support a pupil (or prospective pupil) who has a disability. The Disability Rights
Commission has produced a Code of Practice for Schools. Advice and training
from local healthcare professionals will help schools when looking at what
arrangements they may reasonably make to support a pupil with a disability. 
Local health agencies, local authorities and schools work closely to ensure that
children with complex medical regimes, whether through chronic ill health or
disability, receive the specific support they need so that they can attend school –
whether a special school or mainstream - on a regular basis. Where support is
provided by school staff, they are fully trained by health professionals.
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Primary Care Trusts ensure that:
> Appropriately trained, named nurses are available to all mainstream and special
schools (see Standard 1). Schools have access to appropriate advice, training and
support from local health professionals (including pharmacists) so that they can
make decisions on supporting pupils with their medicines;
> A range of options are explored to enable children and young people to receive
their medicines during the school day, including: 
> Prescribers consider the use of medicines which need to be administered only
once or twice a day (where appropriate) for children and young people so that
they can be taken outside school hours, and
> Prescribers consider providing two prescriptions, where appropriate and
practicable, for a pupil’s medicine: one for home and one for use at school,
avoiding the need for repackaging or relabelling of medicines by parents.
Schools ensure that:
> they have sufficient members of support staff who are employed and
appropriately trained to manage medicines as part of their duties;
> any member of staff undertaking the management of medicines, either
voluntarily or as part of their terms and conditions of service, is appropriately
trained, acting within the scope of their employment, and is indemnified by their
employer’s insurance arrangements, and
> travel-to-school escorts are advised, and trained where appropriate, on what to
do in an emergency.
Schools ensure that they have:
> policies on medicines which are compliant with relevant legislation and
guidelines, and in accordance with their duties under Part 4 of the DDA and do
not discriminate against disabled pupils (or prospective pupils) in relation to
education and associated services;
> clear procedures for staff on managing medicines, including a robust system for
record-keeping and an audit trail, and
> staff managing medicines follow the prescriber’s instructions as noted on the
label on the container of the dispensed medicine. It is not safe practice to follow
relabelled/rewritten instructions or to receive and use repackaged medicines
other than as originally dispensed. 
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11. Children in Special Circumstances
11.1 Some children may be cared for by several different health and social care
professionals and communication between these different professionals is not
always effective.
11.2 When children and young people are living away from home, for all or part
of the time, it is important that information about the nature of any medical
condition and the medicines required, are passed on to all carers and
professionals. Information should also include the role the child or young
person themselves plays in the administration of their medicines.
11.3 Providers of care services for children are regulated by the Care Standards Act
2000 (England and Wales)17, and The Regulation of Care (Scotland) Act
200118. Registered services are monitored according to the National
Minimum Standards. Further information is accessible on www.csci.org.uk
(England); www.wales.gov.uk/subisocialpolicycarestandards (Wales); and
www.carecommission.com (Scotland).
11.4 There have been cases where children have been deliberately harmed by parents
or carers using prescribed medicines. In addition, some children or young
people may harm themselves with prescribed or over-the-counter medicines.
Health care professionals should be alert to the potential for such harm. 
See Standard 5
11.5 Specific groups of children and young people have particular needs, for
example, young offenders need better access to services for drug misuse,
contraception, management of minor ailments and public health measures
such as completion of vaccination programmes.
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If there are concerns that a child is being deliberately harmed through inappropriate
use of prescribed medicines, the Government Guidance Safeguarding Children in
whom Illness is Fabricated or Induced19 is followed.  See Standard 5
Primary Care Trusts and Local Authorities ensure that children and young people in
special circumstances have access to appropriate medicines.
Substance Misuse
11.6 Services and information for children need to be provided in ways that meet
their needs using a range of communication methods. Initiatives include the
Department of Health campaign www.talktofrank.com. Websites such as
www.teenagehealthfreak.com are also useful. See Standard 4
11.7 Some community pharmacies provide services for substance misusers
including needle and syringe exchange schemes, and dispensing and
supervising administration of methadone. The proposed new contractual
framework for community pharmacists is expected to include this as part of
enhanced locally commissioned services.
Primary Care Trusts consider the need for the development of methadone
administration and needle exchange schemes, as part of a treatment programme
for young people.
12. Disabled Children and Young People and those with Complex Health Needs
12.1 Disabled children and young people have special needs in addition to the
wider issues already raised. Some require many different medicines, and the
potential for adverse effects and drug interactions is high. There may be
alternative methods of administration for some medicines, particularly
through feeding tubes, where there is an increased risk of drug-drug and
drug-food interactions. Some specially prepared liquid medicine formulations
may have a short shelf life.
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12.2 With the inclusion of disabled children and young people in mainstream
schools, there should be provision for administration of medicines especially
where complex administration options are required; for example rectal
administration, the use of infusion pumps or oxygen therapy.
See Standards 6 and 8
Primary Care Trusts and Local Authorities ensure that:
> Children and young people who are disabled have access to appropriate
medicines which are carefully monitored and reviewed on a regular basis, and
> Children and young people who need complex interventions with medicines
such as oxygen which requires equipment are provided with suitable equipment
which allows mobility of both the parent or carer and their child and facilitates
school attendance.
13. Children and Young People with Mental Health Disorders
13.1 The choice of treatment and appropriate prescribing can pose a challenge for
services caring for children and young people with mental health problems.
Over one million children have a mental health problem. The evidence base
for the use of medicines in this area is particularly sparse, except for the
treatment of attention deficit hyperactivity disorder (ADHD). 
13.2 The more widespread use of psychoactive medication is relatively recent in
primary care, child mental health and paediatric practice. The recent
Committee on Safety of Medicines20 advice on the use of Selective Serotonin
Reuptake Inhibitors (SSRIs) in children underlines the lack of studies in
children and young people and sends a strong cautionary message about 
safe clinical practice. Many professionals have not yet received sufficient
training in this area to feel competent, and others remain concerned about
the prescribing of medicines for children and young people with mental
health problems. The development of multi-disciplinary training programmes
and improved access to up-to-date information for professionals will help to
address this issue.
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13.3 There is a need for improved communication and partnerships between
professionals who work with children with mental health disorders to ensure that
children and young people receive prompt and appropriate treatment to help
them to address their problems. Some professionals and parents have encountered
negative attitudes to children who require medicines in schools (particularly
those requiring medicines for the treatment of ADHD) and other parents or
carers have found it difficult to access appropriate treatment for their children. 
13.4 Children and young people with mental health disorders which require
treatment with medicines often have persistent and complex problems which
may require the use of a variety of different medicines and doses at different
times. It is important that record-keeping systems are developed locally,
which enable parents or carers, children and young people and relevant
professionals to be clear about the use, dosage and effects of the medicines
used. Medication reviews are particularly valuable for these children and
young people. See section 9
13.5 Acute states of mental illness can occur in acute psychiatric episodes and
sometimes call for rapid decisions about whether medication should be used
to treat a severely distressed child or young person. The development of
guidelines in accident and emergency departments and paediatric wards, which
are developed in collaboration with specialist advice, will ensure that children
and young people in these situations receive safe and appropriate treatment.
See Standards 7 and 9
29
Primary Care Trusts, Local Authorities and NHS Trusts ensure that:
> Professionals working with children and young people with mental health
problems who require medicines, receive training and information regarding
effective treatment, and
> Systems are in place to ensure that this information is regularly reviewed and updated.
Primary Care Trusts, and NHS Trusts ensure that:
> Consistent policies for the appropriate provision of psychoactive medication, and
ongoing support and monitoring of children and young people requiring these
medicines, are developed between services (for example, between paediatricians,
child and adolescent psychiatrists and general practitioners);
> Local arrangements are in place which identify responsibilities for prescribing
and for providing repeat prescriptions;
> Record-keeping systems allow appropriate monitoring and promote safe practice;
> Medication reviews are undertaken for children and young people with a mental
disorder in line with section 9, and
> Protocols are developed in appropriate acute hospital settings, in collaboration
with local CAMHS expertise, for children and young people who require urgent
administration of medicines for mental health disorders.
14. The Role of Pharmacists 
14.1 Pharmacists working in Primary Care, in the community and in hospitals have
a central role in the safe and effective use of medicines for children and
young people.
14.2 Greater use could be made of community pharmacies as a community health
resource. Many consultations with general practitioners or practice nurses for
minor illness, could be dealt with by the community pharmacist. Recent
evidence also shows that 20% of calls to a primary care out-of-hours centre
and at least 8% accident and emergency department consultations could be
handled by a community pharmacist.
30
Medicines for Children and Young People
14.3 Hospital pharmacists, working as part of multidisciplinary teams, may
specialise in neonatal or paediatric pharmacy or in particular specialties, such
as oncology, intensive care, cardiac and renal medicine. They have an
important role in the provision of a comprehensive hospital service for
children and young people. This may include arrangements for the child’s
treatment following discharge including liaising with community services.
Future developments, such as robotic dispensing and electronic prescribing
will enhance the contribution that hospital pharmacies and others can make
to the multi-disciplinary care of children.
14.4 There are examples of local schemes in around 60 Primary Care Trusts where
community pharmacists advise on minor ailments and supply medicines from
a limited formulary for children on the NHS. Data from the first such scheme
now span over four years, and evaluation showed a 40% transfer of
consultations from general practitioners to pharmacists21. Building on the
Best: Choice Responsiveness and Equity in the NHS22, recommends that all
Primary Care Trusts consider carefully targeted schemes to meet the needs of
patients who would otherwise visit their doctor for a prescription.
14.5 Pharmacists may provide Stop Smoking advice and, where appropriate,
referral to an NHS Stop Smoking service. They may also act as Stop Smoking
advisers and are well-placed to do so. (See Department of Health’s national
target on Improving the health of the population.)
14.6 Pharmacists who work in the heart of the community should be encouraged
to focus on the most hard-to-reach and vulnerable families in their
community, working with health visitors, midwives and others to provide
support, information and advice to those who need it most. They also have
an important part to play in promoting healthy lifestyle messages in relation
to nutrition, physical activity and reducing alcohol intake.
31
14.7 Most teenagers (80%) using community pharmacies to access emergency
hormonal contraception generally find the level of privacy acceptable.
However, there is room for improvement through premises design and the
use of consultation areas. Community pharmacists are subject to the Royal
Pharmaceutical Society of Great Britain’s (RPSGB) Code of Ethics23 in
relation to confidentiality. There is evidence that some (20%) young women
accessing emergency hormonal contraception through pharmacies have
concerns about confidentiality. Promoting the confidentiality requirements
that apply to pharmacists through the RPSGB Code of Ethics could increase
young people’s confidence to approach them for advice. See Standard 3
Primary Care Trust pharmacists are engaged in commissioning medicine
management services for children, influencing prescribing by general practitioners,
developing shared care guidelines and ensuring that policies exist for the safe and
effective use of medicines across the primary, secondary and tertiary care interfaces. 
Community pharmacists are used as an appropriately informed and skilled resource
to support self-care for parents, children and young people and sign-posting to
other services. 
Primary Care Trusts and NHS Trusts maximise the contribution of pharmacists, 
their staff and the premises in which they work to improve health and reduce
health inequalities.
Pharmacists should take opportunities to provide healthy lifestyle advice including
advice on physical activity, stopping smoking, reducing alcohol intake and
substance misuse, especially in areas of deprivation. 
Hospital pharmacists ensure that medicines are managed safely and effectively and
that they are appropriate for the age, development and clinical status of the child
or young person. They can also provide advice on the clinical and cost-
effectiveness of medicines.
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15. Clinical Governance Arrangements
15.1 The use of off-label and unlicensed medicines and the lack of evidence on safety
and efficacy have particular implications for clinical governance. Particular issues
to be addressed in this context may include the use of antibiotics.
15.2 Prescribing of antibiotics by general practitioners has been gradually decreasing in
recent years. However, some antibiotic prescribing for children continues to be
inappropriate. Antibiotics are still prescribed for conditions where there is evidence
of little or no benefit e.g. ear infections, sore throats and upper respiratory viral
infections. The Specialist Advisory Committee on Anti-microbial Resistance has a
Paediatric Sub-Group, which is assessing the influence of antibiotic prescribing on
the development of resistance. Hospital prescribing of antibiotics also needs to be
further improved. The Department of Health has invested £12 million over three
years to build on pharmacists’ present involvement in anti-microbial prescribing
and usage, to help reduce the hazards to public health posed by microbial
resistance. Prescribing in children could be one of the considerations for action.
15.3 Primary Care Trusts and NHS Trusts may wish to develop a framework of
what constitutes ‘good prescribing’ for children in primary and secondary care.
Primary Care Trusts and NHS Trusts ensure that:
> Clear policies and procedures are developed by health care providers on the use
of off-label and unlicensed medicines in children in line with Standard 12 of the
Hospital Medicines Management Framework3;
> Prescribing of antibiotics should be in line with best practice and monitored with
a view to reducing antimicrobial resistance;
> Local standards for extemporaneous dispensing of medicines and policies on
purchasing and quality control of unlicensed medicines are developed in line with
standards 33 and 34 of the Hospital Medicine Management Framework3, and
> Health care providers report and monitor medication errors.
Primary Care Trusts and Local Authorities ensure that:
> Monitoring systems are in place for the implementation of guidance on safe use
of medicines in children’s homes and children’s services.
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16. Training and Development
16.1 The delivery of this standard requires sufficient numbers of appropriately
trained professionals who are competent to prescribe, dispense and
administer medicines to children. It will also require sufficient healthcare
professionals, such as school nurses, to support and train professionals and
carers working in schools and other settings.
16.2 Implementing the standard may also involve new roles and ways of working,
for example:
> New support roles within the pharmacy team; 
> Extended roles for community pharmacists;
> Extended roles for nurses, midwives and allied health professionals; and
> Extended roles or new support roles for supporting medicines management
in schools and other settings. 
16.3 The National Prescribing Centre has published competencies for nurse and
pharmacist prescribers. Competencies for paediatric pharmacy practice have
been developed by the Faculty of Neonatal and Paediatric Pharmacy of the
College of Pharmacy Practice. 
16.4 Health professionals who are prescribing, dispensing or administering
medicines for children and young people need to be competent, particularly
regarding the risks and benefits of medicines, shared decision-making, and in
accessing best evidence. There is also evidence from parents of the need for
health professionals to be trained and competent in active listening.
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Primary Care Trusts and NHS Trusts ensure that staff have the relevant
competencies to prescribe, dispense and administer medicines for children and
young people.
Staff involved in medicines management for children and young people have the
appropriate Common Core skills, knowledge and competencies (including child
protection) set out in Standard 3. 
Healthcare professionals who are prescribing, dispensing or administering
medicines for children and young people are competent in:
> The safe and effective use of medicines in children;
> Calculating drug doses, and administering medicines to children;
> Understanding the risks and benefits of medicines in relation to children;
> The needs of ethnic minorities, and cultural differences in beliefs about illness
and the use of medicines;
> Accessing best evidence on the effectiveness of medicines;
> Giving information on medicines to children and parents in a clear way;
> Concordance, including active listening and shared decision-making 
with children and parents, and
> The recording of significant events and their use in multi-disciplinary 
and multi-agency audits.
Primary Care Trusts and Local Authorities and NHS Trusts ensure that:
> All appropriate professionals caring for children and young people receive
specific training in medicines management for children and young people, and 
> Training in safe medication practice is undertaken by professionals and carers
working in a whole range of settings, including foster carers, residential social
workers, respite care workers, early years and childcare workers, and education
staff. In addition, better knowledge and understanding of psychoactive
medication for treatment of mental health problems is required for staff who
work with children and young people with mental health problems, in all sectors.
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